Empowering therapeutic antibodies with IFN-α for cancer immunotherapy.

Empowering therapeutic antibodies with IFN-α for cancer immunotherapy.

Type 1 IFNs stimulate secretion of IP-10 (CXCL10) which is a critical chemokine to recruit effector T cells to the tumor microenvironment and IP-10 knockout mice exhibit a phenotype with compromised effector T cell generation and trafficking. Type 1 IFNs also induce MHC class 1 upregulation on tumor...

Full description

Bibliographic Details
Main Authors: Jun Guo, Yu Xiao, Ramesh Iyer, Xin Lu, Marc Lake, Uri Ladror, John Harlan, Tanushree Samanta, Medha Tomlinson, Gail Bukofzer, Cherrie Donawho, Alex Shoemaker, Tzu-Hsuan Huang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0219829

Internet

https://doi.org/10.1371/journal.pone.0219829

Similar Items